You are currently viewing a new version of our website. To view the old version click .
by
  • Marco Pizzoferrato1,2,*,†,
  • Roberto de Sire2,*,† and
  • Fabio Ingravalle2
  • et al.

Reviewer 1: Anonymous Reviewer 2: Anonymous

Round 1

Reviewer 1 Report

Pizzoferrato and colleagues report the percentage of sarcopenia in an IBD cohort. I have only some minor suggestions

Minor points.

Table 1. Specify the biologics used for the treatment

Figure 1 The term prevalence is not appropriate, because this is a rather small population. Please state instead percentage.

How many patents with sarcopenia were treated with seroids?

Author Response

Dear Reviewer 1, 

thank you for your comments and suggestions.  We proceeded to make the requested changes

Reviewer 2 Report

Authors presented very elegant and interesting study, which is highlighting the fact, that IBD are systemic diseases.

I have one small remark - please rewrite the second part in the conclusions in abstract. Should be more clear.

Author Response

Dear Reviewer 2,

thank you for your comments and suggestions. We have rewrited the second part in the conclusions in abstract.